RECURSION PHARMACEUTICALS, INC.
RECURSION PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 20.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 5, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 15, 2027 | Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Trial Milestone | Phase 1/Phase 2 |
| October 30, 2028 | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer | Trial Milestone | Phase 1/Phase 2 |
| January 15, 2031 | REC-7735 in Participants With Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
Track RXRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open RXRX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.